Cargando…

Expanded criteria for pretreatment staging CT in breast cancer

BACKGROUND: There is wide variation in the approach to staging for distant metastatic disease in breast cancer. This study sought to identify factors predictive of distant metastatic disease at presentation to enable appropriate selection of patients for pretreatment CT. METHODS: Data were collected...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszkowski, N, Lam, S S, Copson, E, Cutress, R I, Oeppen, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955978/
https://www.ncbi.nlm.nih.gov/pubmed/33715004
http://dx.doi.org/10.1093/bjsopen/zraa006
_version_ 1783664354159230976
author Roszkowski, N
Lam, S S
Copson, E
Cutress, R I
Oeppen, R
author_facet Roszkowski, N
Lam, S S
Copson, E
Cutress, R I
Oeppen, R
author_sort Roszkowski, N
collection PubMed
description BACKGROUND: There is wide variation in the approach to staging for distant metastatic disease in breast cancer. This study sought to identify factors predictive of distant metastatic disease at presentation to enable appropriate selection of patients for pretreatment CT. METHODS: Data were collected retrospectively for all patients with newly diagnosed breast cancer (screening and symptomatic) over 3 years (2014–2017). Detailed demographic, pathological, biological, and management data were recorded at presentation, and outcome data were recorded after follow-up. Binomial logistic regression was used to identify variables independently associated with distant metastatic disease at presentation. RESULTS: A total of 1377 patients with newly diagnosed breast cancer were identified, of whom 1025 had complete data; 323 staging CT examinations were performed. Distant metastases were identified at presentation in 47 (4.6 per cent). Some 30 of 47 patients with metastatic disease met established criteria for staging (T4, recurrence, symptoms of possible distant metastases), leaving 17 patients with metastatic disease potentially missed by use of these criteria alone. Multivariable analysis showed that tumour size at least 3 cm combined with sonographically abnormal axillary lymph nodes predicted a high probability of distant metastatic disease at presentation (positive predictive value 18.8 per cent, odds ratio 4.83, P < 0.001). Addition of this criterion increased the positive CT rate to 17.1 per cent. CONCLUSION: Selective pretreatment CT staging can be further optimized with the addition of tumour size at least 3 cm with abnormal axillary nodes to established staging criteria.
format Online
Article
Text
id pubmed-7955978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79559782021-03-18 Expanded criteria for pretreatment staging CT in breast cancer Roszkowski, N Lam, S S Copson, E Cutress, R I Oeppen, R BJS Open Original Article BACKGROUND: There is wide variation in the approach to staging for distant metastatic disease in breast cancer. This study sought to identify factors predictive of distant metastatic disease at presentation to enable appropriate selection of patients for pretreatment CT. METHODS: Data were collected retrospectively for all patients with newly diagnosed breast cancer (screening and symptomatic) over 3 years (2014–2017). Detailed demographic, pathological, biological, and management data were recorded at presentation, and outcome data were recorded after follow-up. Binomial logistic regression was used to identify variables independently associated with distant metastatic disease at presentation. RESULTS: A total of 1377 patients with newly diagnosed breast cancer were identified, of whom 1025 had complete data; 323 staging CT examinations were performed. Distant metastases were identified at presentation in 47 (4.6 per cent). Some 30 of 47 patients with metastatic disease met established criteria for staging (T4, recurrence, symptoms of possible distant metastases), leaving 17 patients with metastatic disease potentially missed by use of these criteria alone. Multivariable analysis showed that tumour size at least 3 cm combined with sonographically abnormal axillary lymph nodes predicted a high probability of distant metastatic disease at presentation (positive predictive value 18.8 per cent, odds ratio 4.83, P < 0.001). Addition of this criterion increased the positive CT rate to 17.1 per cent. CONCLUSION: Selective pretreatment CT staging can be further optimized with the addition of tumour size at least 3 cm with abnormal axillary nodes to established staging criteria. Oxford University Press 2021-03-14 /pmc/articles/PMC7955978/ /pubmed/33715004 http://dx.doi.org/10.1093/bjsopen/zraa006 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Roszkowski, N
Lam, S S
Copson, E
Cutress, R I
Oeppen, R
Expanded criteria for pretreatment staging CT in breast cancer
title Expanded criteria for pretreatment staging CT in breast cancer
title_full Expanded criteria for pretreatment staging CT in breast cancer
title_fullStr Expanded criteria for pretreatment staging CT in breast cancer
title_full_unstemmed Expanded criteria for pretreatment staging CT in breast cancer
title_short Expanded criteria for pretreatment staging CT in breast cancer
title_sort expanded criteria for pretreatment staging ct in breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955978/
https://www.ncbi.nlm.nih.gov/pubmed/33715004
http://dx.doi.org/10.1093/bjsopen/zraa006
work_keys_str_mv AT roszkowskin expandedcriteriaforpretreatmentstagingctinbreastcancer
AT lamss expandedcriteriaforpretreatmentstagingctinbreastcancer
AT copsone expandedcriteriaforpretreatmentstagingctinbreastcancer
AT cutressri expandedcriteriaforpretreatmentstagingctinbreastcancer
AT oeppenr expandedcriteriaforpretreatmentstagingctinbreastcancer